Mycobacterium avium complex

Newer antimycobacterial drugs

Bedaquiline, tedizolid, linezolid, and omadacycline have demonstrated in vitro activity against clinical isolates of MAC. These agents may be considered as an additional fourth drug to be added on to currently recommended antimycobacterial regimens in people with refractory MAC disease. However, there is insufficient clinical trial or observational data to support formal recommendations in this setting.[8]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Disseminated mycobacterium avium complex disease. 2024 [internet publication]. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/disseminated ​